Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anagrelide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 20/20 | 1.00 |
| ▸ | PDE3A known ✓ | Q14432 | 20/20 | 1.00 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anagrelide SCHEMBL29491059 | 1.00 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL5060881 | 1.00 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9046734 | 0.99 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1568712 | 0.99 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1449704 | 0.99 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL318593 | 0.99 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL729172 | 0.97 | PDE3B (0.94) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL16335881 | 0.93 | PDE3B (0.87) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1664162 | 0.92 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL28341325 | 0.92 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23847 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12595232-B2 | DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor | BAHCESEHIR UNIVERSITESI (TR) | 2026-04-07 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12582672-B2 | Vanadium compositions and methods for treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| EP-0961616-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1998010765-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-03-19 | — | — | WO | claimed |
| US-5391737-A | Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one | EGIS GYOGYSZERGYAR (HU) | 1995-02-21 | — | — | US | claimed |
| US-4444777-A | ANTICOAGULANT | BRISTOL-MYERS COMPANY (US) | 1984-04-24 | — | — | US | claimed |
| US-4436934-A | SYNERGISTIC COMBINATION WITH ANAGRELIDE; THROMBOXANE SYNTHETASE INHIBITORS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1984-03-13 | — | — | US | claimed |
| US-4432980-A | ANAGRELIDE WITH EITHER ZOMEPIRAC, NAPROXEN; OR ISUPROFEN | BRISTOL-MYERS COMPANY (US) | 1984-02-21 | — | — | US | claimed |
| US-4357330-A | Pharmaceutical compositions | BRISTOL-MYERS COMPANY (US) | 1982-11-02 | — | — | US | claimed |
| US-4208521-A | Process for the preparation of imidazo[2,1-b]quinazolinones | BRISTOL-MYERS COMPANY (US) | 1980-06-17 | — | — | US | claimed |